Rituximab-induced interstitial pneumonitis: report of two cases and literature review.
- Author:
Bao-Hong PING
1
;
Chun-Yan YUE
;
Yang-Min ZHU
;
Ya GAO
;
Bin WU
;
Jia-Qiong HONG
Author Information
1. Huiqiao Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. pbh66@126.com
- Publication Type:Case Reports
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
adverse effects;
Disease Susceptibility;
Humans;
Lung Diseases, Interstitial;
chemically induced;
Rituximab;
Tomography, X-Ray Computed
- From:
Journal of Southern Medical University
2015;35(1):129-132
- CountryChina
- Language:Chinese
-
Abstract:
We report two cases of rituximab (RTX)-induced interstitial pneumonia in two lymphoma patients receiving RTX treatment. Interstitial pneumonia was successfully managed in these two cases after a one-week-long intervention with corresponding treatments without affecting further treatment of the primary disease. RTX-induced interstitial pneumonia is characterized by a latent onset with an unclear pathological mechanism and absence of typical symptoms. High-resolution CT scan can provide valuable evidence for early diagnosis of RTX-induced interstitial pneumonia, which might be attributed partially to an increased susceptibility to P. jirovecii and fungal infection due to prolonged RTX treatment.
